HomeCompareOLYMY vs PFE

OLYMY vs PFE: Dividend Comparison 2026

OLYMY yields 1.42% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OLYMY wins by $15.84M in total portfolio value
10 years
OLYMY
OLYMY
● Live price
1.42%
Share price
$9.87
Annual div
$0.14
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.89M
Annual income
$13,992,552.12
Full OLYMY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — OLYMY vs PFE

📍 OLYMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOLYMYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OLYMY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OLYMY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OLYMY
Annual income on $10K today (after 15% tax)
$120.57/yr
After 10yr DRIP, annual income (after tax)
$11,893,669.30/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, OLYMY beats the other by $11,871,349.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OLYMY + PFE for your $10,000?

OLYMY: 50%PFE: 50%
100% PFE50/50100% OLYMY
Portfolio after 10yr
$7.97M
Annual income
$7,009,405.42/yr
Blended yield
87.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

OLYMY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.3
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OLYMY buys
0
PFE buys
0
No recent congressional trades found for OLYMY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOLYMYPFE
Forward yield1.42%6.13%
Annual dividend / share$0.14$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$15.89M$49.6K
Annual income after 10y$13,992,552.12$26,258.71
Total dividends collected$15.71M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: OLYMY vs PFE ($10,000, DRIP)

YearOLYMY PortfolioOLYMY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,984$283.69$9,153$693.39+$1.8KOLYMY
2$12,335$582.42$8,593$849.25+$3.7KOLYMY
3$14,421$1,222.56$8,336$1,066.78+$6.1KOLYMY
4$18,102$2,671.62$8,437$1,384.80+$9.7KOLYMY
5$25,638$6,268.36$9,013$1,875.40+$16.6KOLYMY
6$44,026$16,593.91$10,306$2,680.72+$33.7KOLYMY
7$100,371$53,263.34$12,820$4,101.38+$87.6KOLYMY
8$334,370$226,972.80$17,673$6,826.70+$316.7KOLYMY
9$1,771,088$1,413,311.85$27,543$12,591.86+$1.74MOLYMY
10$15,887,616$13,992,552.12$49,560$26,258.71+$15.84MOLYMY

OLYMY vs PFE: Complete Analysis 2026

OLYMYStock

Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting of CRC devices and HPB devices/hemostasis products; endoscopic solutions ecosystem products, including intelligent ecosystem operating software platforms, and AI insights and computer-aided detection/diagnosis products; reprocessing products, such as endoscope reprocessors, chemicals, accessories, and peripherals; and medical services, which include repair center services. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat; and gastroenterology devices and gynecology products. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.

Full OLYMY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this OLYMY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OLYMY vs SCHDOLYMY vs JEPIOLYMY vs OOLYMY vs KOOLYMY vs MAINOLYMY vs JNJOLYMY vs MRKOLYMY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.